UPM Pharmaceuticals Enhances Pre-Formulation Capabilities
UPM Pharmaceuticals recently announced it has purchased and qualified a TA Instruments Q20 Auto MDSC (Differential Scanning Calorimeter), and a TA Instruments Q50 TGA (Thermogravimetric Analyzer). These pieces of equipment greatly enhance UPM’s ability to provide comprehensive pre-formulation studies, as well as support analytical testing of challenging formulations such as poorly soluble compounds.
“UPM sees these new pieces of analytical equipment combined with our already highly qualified and experienced analytical team as a powerful combination for our clients who are trying to make the best and most cost-effective decisions about investment of precious research funds. And further is looking for a partner that can perform the latest and best analysis with the most reliable equipment available in the pre-formulation stage of development,” said UPM’s President, Jim Gregory.
UPM Pharmaceuticals, Inc. is a Baltimore-based contract development and manufacturing organization providing customized formulation development, manufacturing, and analytical services to pharmaceutical, biotechnology, academic, and veterinary clients. Fully appreciating that time-to-market is critical, UPM offers remarkably flexible, affordable, and rapid outsourcing services designed to meet clients’ specific development and manufacturing needs. Their clients represent both small and large companies within the pharmaceutical and biotechnology industries, and academic institutions who have a focus on clinical studies.
UPM provides high-quality pharmaceutical drug development services, including formulation development, cGMP manufacturing, analytical methods development, and stability testing. They are characterized by the quality, speed, and thoroughness with which they complete all their projects. UPM’s clients enjoy service that is customized and fast with total quality management characteristic of a customer-focused business. Their history includes successful collaborative interactions with virtual to multi-million dollar companies providing them with customized product development services and solutions. UPM focuses on drug development for dosages with oral routes of administration, in solid dosage forms such as capsules and tablets. To learn more about UPM, please visit www.upm-inc.com.
Total Page Views: 990
